By Fineline Cube 
Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series A financing round exceeding RMB 200 million. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow‑on commitments from existing backers Shunxi Fund and Qiming Venture Partners.
Deal Structure & Capital Allocation
| Item | Detail |
|---|---|
| Total Capital Raised | > RMB 200 million (≈ US$28 million) |
| Lead Investor | Beijing Medical and Health Industry Investment Fund |
| Co‑Investors | INCE Capital, Guanghua Wutong, Proxima Ventures |
| Follow‑On Investors | Shunxi Fund, Qiming Venture Partners |
| Primary Use of Proceeds | • Initiate pivotal Phase III trial of BR005 (CGRP small‑molecule) • Expand R&D pipeline for novel analgesics targeting chronic pain |
| Timeline | Phase III enrollment slated to begin Q1 2026 |
Scientific & Clinical Overview
- BR005: The first domestic, first‑in‑class calcitonin‑gene‑related peptide (CGRP) small‑molecule antagonist designed for severe chronic pain.
- Target Indications:
- Head & facial pain (e.g., cluster headache, trigeminal neuralgia)
- Neuropathic pain (post‑herpetic neuralgia, diabetic neuropathy)
- Musculoskeletal pain (osteoarthritis, chronic low‑back pain)
- Pre‑clinical & Early Clinical Data: Demonstrated ≥ 70 % reduction in pain scores versus placebo in Phase IIb proof‑of‑concept studies, with a favorable safety profile and once‑daily oral dosing.
Market Opportunity
- Chronic pain prevalence in China exceeds 100 million patients, representing a $15 billion unmet market.
- CGRP antagonism is a validated mechanism in migraine; Brise’s small‑molecule platform offers oral convenience and broader pain‑type applicability versus injectable antibodies.
- Successful Phase III results could position BR005 as a first‑to‑market oral CGRP analgesic, opening global licensing and partnering opportunities.
Investor & Strategic Implications
- The RMB 200 M infusion strengthens Brise’s cash runway through Phase III and early pipeline expansion, reducing dilution risk for existing shareholders.
- Participation by state‑linked Beijing Medical and Health Industry Investment Fund signals strong government endorsement for innovative pain‑management therapeutics.
- Sherpa Healthcare Partners will continue to provide strategic guidance and access to China’s regulatory network, accelerating market entry.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Brise Pharma’s financing, development timeline, and commercial potential of BR005. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and market acceptance.-Fineline Info & Tech